No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: A2 - Guideline
|
MYC overexpression
MYC overexpression
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
Resistant: C3 – Early Trials
|
EZH2 overexpression
EZH2 overexpression
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
Resistant: C3 – Early Trials
|
MYC rearrangement
MYC rearrangement
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
rituximab
Sensitive: C3 – Early Trials
|
BCL6 rearrangement
BCL6 rearrangement
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
rituximab
Sensitive: C3 – Early Trials
|
